STOCK TITAN

Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
AI

Omada Health (OMDA) presented research on AI-powered meal feedback and yearlong GLP-1 medication outcomes at ObesityWeek 2026.

In a randomized analysis of 13,852 members, Meal Map users were more likely than controls to log at least three meals in their first month (41.1% versus 36.0%). Among members meeting that tracking threshold, week-16 weight loss was 3.47% with Meal Map versus 3.02% without it. Meal Map users also had 34% greater odds of meeting the tracking threshold every month through 16 weeks.

A separate analysis of 969 adults without diabetes found 71% stayed on GLP-1 medication at 52 weeks after their first fill. Those continuing for a full year lost an average 18.4% of body weight; the full cohort averaged 16.3% weight loss at 12 months. Greater engagement was associated with higher odds of medication continuation and, among continuing users, reaching 15% weight loss.

Loading...
Loading translation...
9 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointMeal Map users logged at least three first-month meals more often than controls: 41.1% versus 36.0%.
  • Moderate pointGLP-1 medication continuation reached 71% at 52 weeks after the first fill.
  • Moderate pointThe full GLP-1 cohort averaged 16.3% body-weight loss at 12 months, regardless of time on medication.
  • Minor pointMeal Map users had 34% greater odds of tracking at least three meals monthly through 16 weeks.
  • Minor pointWeek-16 weight loss was 3.47% versus 3.02% among Meal Map users versus controls meeting the first-month tracking threshold.
4 minor points
  • Minor pointFull-year GLP-1 users averaged 18.4% body-weight loss; Omada characterized this as comparable to clinical trial outcomes.
  • Minor pointEach additional five weekly engagement actions was associated with 28% greater adjusted odds of medication continuation.
  • Minor pointAmong continuing users, five additional weekly engagement actions were associated with 28% greater odds of reaching 15% weight loss.
  • Minor pointEarly findings among members stopping medication suggested potential for weight maintenance after discontinuation.

Negative

  • None.

Key Figures

Analysis size: 13,852 members Meal tracking in first month: 41.1% vs. 36.0% Ongoing meal tracking: 34% greater odds +5 more
Analysis size
13,852 members
Behavior change program analysis
Meal tracking in first month
41.1% vs. 36.0%
Members tracking at least three meals; Meal Map vs. control
Ongoing meal tracking
34% greater odds
Tracking at least three meals monthly through 16 weeks with Meal Map
Weight loss at week 16
3.47% vs. 3.02%
Among members tracking at least three meals in their first month
GLP-1 analysis size
969 adults
Adults without diabetes in the 12-month Care Track analysis
Medication persistence
71%
Stayed on GLP-1 medication at 52 weeks after first fill
Weight loss among persistent members
18.4% of body weight
Average loss among members who stayed on medication for a full year
Full-cohort weight loss
16.3% of body weight
Average loss at 12 months regardless of time on medication

Previous AI Reports

1 past event · Latest: Oct 01
Same Type 1 event
  1. Oct 01

    Meal Map launch

    24h Move
    +1.4%

    Meal Map launch described pilot evidence of increased meal engagement versus traditional approaches.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, pharmacy claims, semaglutide, tirzepatide
4 terms
glp-1 medical
"In Omada’s GLP-1 Care Track, 71% of members stayed on their medication"
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
pharmacy claims technical
"Medication persistence was confirmed through pharmacy claims."
Pharmacy claims are requests submitted to an insurer or pharmacy benefits manager asking for payment or reimbursement for a prescription drug dispensed to a patient. They act like receipts a pharmacy sends to a payer to show what was provided and how much should be covered; approval rates, processing speed, and paid amounts directly affect cash flow, revenue, patient access and cost forecasting for drug makers, insurers and healthcare investors.
semaglutide medical
"approximately 16-17% with semaglutide and approximately 20% with tirzepatide"
Semaglutide is a medication originally developed to help manage blood sugar levels in people with diabetes, but it also promotes weight loss. It works by mimicking a natural hormone that helps control appetite and insulin release. For investors, its potential to influence healthcare and weight management markets makes it a significant product in the pharmaceutical industry.
tirzepatide medical
"approximately 16-17% with semaglutide and approximately 20% with tirzepatide"
Tirzepatide is a prescription medicine that helps lower blood sugar and reduce appetite by activating two hormones that regulate insulin and hunger; think of it as a two-in-one switch that calms the body’s sugar spikes and decreases cravings. Investors watch it because regulatory approvals, clinical results, pricing and patient demand determine sales potential and competitive impact on companies in diabetes and obesity treatment markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Omada’s AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16.

In Omada’s GLP-1 Care Track, 71% of members stayed on their medication for a full year, and those who did lost 18.4% of body weight, comparable to clinical trials.

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced two presentations at ObesityWeek 2026, taking place November 14-17, 2026, in Washington, D.C. The research looks at the support people need between doctor visits, including building food habits that fit daily life and staying on GLP-1 treatment for a full year to get the most out of the medication.

Poster Presentation #308: AI-Powered Meal Feedback Is Linked to More Meal Tracking and Greater Weight Loss in a Virtual Lifestyle Program

The first presentation highlights how Omada’s AI-powered tool, Meal Map, may help people who struggle with emotional eating and cravings build tracking habits that support weight loss.1 Meal Map, now available in Omada’s cardiometabolic programs, provides members with real-time, AI-powered feedback on every meal logged, focusing on nutrient quality rather than restrictive eating. Instead of scoring foods as “good” or “bad,” AI technology identifies the nutrient-dense parts of a meal and the gaps in its balance alongside actionable guidance for future meals.

In this analysis, 13,852 members who joined Omada’s behavior change program between September and November 2025 and reported emotional eating, trouble managing cravings or snacking often were randomized into two groups. The control group received Omada’s core nutrition features, including meal tracking, care team alerts when nutrition patterns changed, and the OmadaSpark chatbot, an AI-powered resource for nutrition education. The second group received those same features plus Meal Map.1

Compared with the control group, Meal Map members1:

  • Were more likely to track at least three meals in their first month (41.1% vs. 36.0%).
  • Had 34% greater odds of tracking at least three meals every month through 16 weeks.
  • Lost more weight at week 16 if they tracked at least three meals in their first month (3.47% vs. 3.02%).

Alison Megliola, MS, RD, CDCES, Director of Clinical Product, presented the poster on Saturday, November 14, 2026, from 7:30 to 8:30 PM ET at ObesityWeek 2026.

Poster Presentation #533: Virtual Lifestyle Program Support for GLP-1 Therapy: 12-Month Persistence and Weight Outcomes in Adults With Obesity

The second presentation builds on 12-month GLP-1 Care Track results Omada shared in January 2026.2 The analysis included 969 adults without diabetes who started a GLP-1 between 60 days before and 30 days after enrolling in Omada’s GLP-1 Care Track between June and September 2024. Medication persistence was confirmed through pharmacy claims.3

Key findings include3:

  • 71% stayed on GLP-1 medication at 52 weeks after their first fill.
  • Members who stayed on medication the full year lost an average of 18.4% of body weight, comparable to clinical trial outcomes (approximately 16-17% with semaglutide and approximately 20% with tirzepatide),4,5 and the full cohort lost an average of 16.3% of body weight at 12 months regardless of time on medication.
  • Each additional five weekly engagement actions was associated with 28% greater adjusted odds of staying on medication and, among those who stayed on, 28% greater odds of reaching 15% weight loss.
  • Among members who stopped medication, early findings suggested potential for weight maintenance after discontinuation.

Omada’s GLP-1 Care Track supports members taking GLP-1s between doctor visits, and if they stop, helps with the transition off medication. Each member works with a dedicated care team to receive ongoing support on side effects, medication questions and GLP-1-specific nutrition, along with access to GLP-1 peer communities and digital tools for meal logging, behavior tracking and nutrition. Members also have access to an exercise specialist and customized plans to maintain lean mass. In this analysis, members who engaged with Omada’s support more often were more likely to stay on their medication.

“Patients often leave a doctor’s visit with good advice about how to eat, and then they have to make it work on their own until the next appointment,” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “That’s harder for people who deal with emotional eating or cravings, because those moments rarely happen in the exam room. Feedback right after a meal is logged gives them support when they need it. Across both analyses, members who stayed engaged between visits did better, whether that meant building a tracking habit or staying on a GLP-1 for a full year.”

The GLP-1 Care Track analysis was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.

Omada Health’s Senior Clinical Research Scientist, Susan M. Devaraj, PhD, MS, RD, presented the analysis on Sunday, November 15, 2026, from 2:30 to 3:30 PM ET at ObesityWeek 2026.

Omada Health
Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today’s healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

Media Contact
Rose Ramseth
press@omadahealth.com

References

  1. Naqvi JB, Stanton LA, Linesch S, et al. AI-powered meal feedback is linked to more meal tracking and greater weight loss in a virtual lifestyle program. Poster presented at: ObesityWeek 2026; November 14-17, 2026; Washington, D.C.
  2. Omada Health. Omada Health's GLP-1 behavior change companion programs help drive lasting, long-term weight loss. News release. Published January 8, 2026. Accessed November 14, 2026. https://www.omadahealth.com/resource-center/omada-healths-glp-1-behavior-change-companion-programs-help-drive-lasting-long-term-weight-loss
  3. Devaraj SM, Napoleone J, Naqvi JB, Chang H, Linke S. Virtual lifestyle program support for GLP-1 therapy: 12-month persistence and weight outcomes in adults with obesity. Poster presented at: ObesityWeek 2026; November 15, 2026; Washington, D.C.
  4. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Omada Health's Meal Map research show about weight loss?

Among members who logged at least three meals in their first month, week-16 weight loss was 3.47% with Meal Map versus 3.02% in the control group. Meal Map users were also more likely to meet that first-month tracking threshold: 41.1% versus 36.0%.

What were Omada Health's 12-month GLP-1 Care Track results?

71% of members stayed on GLP-1 medication at 52 weeks after their first fill. Members continuing for a full year lost an average of 18.4% of body weight, while the full cohort averaged 16.3% weight loss at 12 months regardless of time on medication.

Who participated in Omada Health's Meal Map study, and what did the control group receive?

The randomized analysis included 13,852 members who joined Omada's behavior change program between September and November 2025 and reported emotional eating, trouble managing cravings or frequent snacking. Controls received meal tracking, care-team alerts when nutrition patterns changed, and the OmadaSpark nutrition-education chatbot. The other group received those features plus Meal Map.

How did Omada Health select GLP-1 Care Track study participants and verify medication continuation?

The analysis included 969 adults without diabetes who started a GLP-1 between 60 days before and 30 days after enrolling in the Care Track between June and September 2024. Medication continuation was confirmed through pharmacy claims.

Keep reading